ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

CPO-107

Also written as “CPO107”, “JMT601 Injection” and “JMT601”.

Its studies are mostly in Lymphoma, Non-Hodgkin · Glomerulonephritis, Membranous · Lymphoma, B-Cell, led by 2 companies.

Drug pageCPO-107: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Jun 11, 20253 company-led studies, 2 open or runningNext primary completion: Apr 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group22 open or runningphase 2since Jun 11, 2025Jul 19, 2023Apr 1, 2027phase 2 · NCT07029139
Conjupro Biotherapeuticsits history only10 open or runningphase 1since Mar 2, 2021Mar 2, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of CSPC Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 19, 2023First study: phase 1 study in Lymphoma, B-CellFirst studyNCT06725524 · 186 planned · China
  2. Jun 11, 2025Phase 2 study in Primary Membranous NephropathyNCT07029139 · 156 planned

Ahead

  1. Apr 1, 2027Primary completion: phase 2 study in Primary Membranous NephropathyNCT07029139

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 CSPC Pharmaceutical Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07029139Primary Membranous Nephropathy2Not yet recruitingApr 1, 2027156
NCT06725524Lymphoma, B-Cell · China1RecruitingDec 31, 2025186

How it is read

Names in the registry

  • “CPO107”, 1 entry
  • “JMT601 Injection”, 1 entry
  • “JMT601”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.